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SUMMARY 
The approval of immune checkpoint inhibitors has revolutionised cancer therapy. Even so, 
there remains an urgent need to find treatments for patients that do not respond to or are 
not eligible to receive this class of drugs. Given this, many more innovative approaches are 
now being developed to re-direct the immune system towards tumour cells, ranging from 
small molecules and novel biologics to cell therapies and gene therapy approaches. The 
aim of the one-day meeting was to bring together renowned experts from academia and 
industry to discuss the latest immunotherapy advances and highlight how these discoveries 
form the basis of novel drugs that are designed to target key immunology pathways and 
transform the lives of cancer patients. This meeting was aimed at students and practicing 
professionals from academia and industry looking to gain an understanding of the 
pathological mechanisms at play within immune-oncology and their targeting in discovery 
and development of novel immunotherapies. 
This symposium was held at St.Hilda’s College, Cowley Place, Oxford, OX4 1DY, UK and 
sponsored by AstraZeneca. 
 Session 1: Introduction to novel immunotherapies and T-cell targets 
Sifting the surfeit of novel immunotherapies: a phase 1 triallist’s view 
The first presentation of the day was given by Professor Mark Middleton, University of Oxford, 
who outlined the challenges of developing new immune-oncology agents.  In particular, he 
highlighted that despite the revolutionary impact of immune checkpoint inhibitors in the 
treatment of melanoma, non-small cell lung cancer and other tumours, the majority of cancer 
patients do not stand to benefit from immunotherapy.  Professor Middleton noted that most 
common tumour types have largely proved refractory to this approach and even in sensitive 
cancers only a minority of those patients treated derive benefit. This has driven a wave of 
clinical trials evaluating novel agents designed to overcome what we understand to be the 
key obstacles to successful treatment or seeking to identify new indications for existing 
immunotherapies.  In addition, the potential approaches to be tested far outstrip the available 
patient population for clinical studies and there is no agreed basis for identifying or prioritising 
the most promising drugs or targets.  
Professor Middleton went on to emphasise that mechanistic understanding, incorporating 
both biological and clinical end points, is required to better develop new treatments.  He 
emphasised that results need to be interpreted within the context of the tumour immunology 
of the patient population, which if not specified in the protocol, might be skewed towards 
particular groups such as microsatellite stable colorectal cancer or checkpoint inhibitor 
refractory patients. The tools available to researchers are improving all the time and although 
analyses are not cheap they represent a tiny fraction of the cost of phase 1 clinical studies.  
Professor Middleton proposed five key factors for improving the success of testing drugs in 
phase 1 studies, namely testing agents in potentially curable (earlier stage) patients, 
acquisition and detailed analysis of tumour and normal tissue, linking changes to potential 
surrogate tissue markers, understanding the biological effects of dosing and the ability to 
explain clinical results in other clinical studies. 
Whilst many patients have achieved clinical benefit with immuno-oncology therapies such as 
Ipilimumab, Pembrolizumab and Nivolumab, Professor Middleton explained that many 
patients do not benefit from these treatments including 40 to 70% of patients with potentially 
sensitive diseases, people whose tumours are growing too fast, patients with breast, prostate 
and colorectal cancer, people with brain metastases and patients with autoimmune conditions 
or organ transplants. 
Professor Middleton outlined four factors that determine sensitivity to immunotherapy namely, 
mutational burden, tumour sensitivity to immune effects (e.g. MHC expression and IFN 
sensitivity, exhaustion markers), checkpoint expression and immune cell infiltrate (e.g. 
intratumoural T cells). 
In the last part of his presentation Professor Middleton gave an example of the ImmTAC 
(immune mobilising monoclonal T-cell receptor against cancer) molecule Tebentafusp which 
binds a gp100 peptide presented by HLA-A2 on tumour cells.  Mechanistic results from 
clinical studies suggest that patients with the greatest increase in CXCL10 have greater 
tumour shrinkage and longer survival. 
   
New T-cell Receptor Targets by dissection of successful cancer immunotherapy 
The next presentation was given by Professor Andrew Sewell from University of Cardiff.  He 
outlined that over 20% of melanoma patients that have been refractory to other treatments 
undergo complete lasting remission after adoptive cell transfer of tumour-infiltrating 
lymphocytes (TILs). Dissection of these extraordinary successes by examining the dominant 
tumour-reactive T-cell clonotypes in the TIL infusion product and patient blood after 'cure' has 
revealed some surprising, exciting new HLA-restricted and non-HLA restricted T-cell targets 
that are expressed by many other tumour types.  Several of the new broadly expressed 
HLA-restricted cancer epitopes were unexpected as the proteins they derive from are thought 
to be expressed in some healthy cell types. In some cases, patients received billions of 
activated T-cells with these specificities within their TIL infusion product that persist in the 
blood years after complete remission and large populations of such cells can be found in 
other remission patients. These data suggest that targeting these new epitopes is safe. The 
Sewell group have also used a whole genome CRISPR forward genetic screening to identify 
the cancer-specific ligands recognised by ‘HLA-agnostic’ T cells. Professor Sewell described 
how such ligands, and the T-cell receptors that recognise them, could be used to build 
therapies for most cancers in all individuals as they circumvent the hurdle of only a minority 
of patients having any given HLA type.  
 
Professor Sewell also demonstrated how altered peptide ligands could be used to skew T-
cell responses towards effective T-cell clonotypes identified in patients successfully treated 
with TIL therapy. This approach was used to induce T-cell lines from the blood of patients 
with several types of cancer. These altered peptide ligand-induced T-cell lines were shown 
to be far more effective at killing autologous tumour lines than lines induced by the natural 
peptide ligand. In Professor Sewell’s opinion, new approaches to cancer vaccination that 
focus on the quality of the response induced at the clonotypic level rather than the quantity 
of the response could revolutionise future prospects for successful cancer vaccination. 
 
 Session 2: TCR-based therapies 
Advancing the ImmTAC TCR-Based Bi-specific Biologic Platform: Preclinical data on 
the next clinical ImmTAC molecule 
Dr. Joseph Dukes from Immunocore Ltd continued on the theme of T-cell receptors (TCRs) 
and gave an overview of Immunocore’s ImmTAC technology. ImmTAC molecules are a novel 
class of biologics that consist of a soluble TCR-based targeting domain and an anti-CD3 
effector domain. Utilising TCRs as targeting domains provides access to potentially clean 
and cancer- or tissue-specific targets due to recognition of Class I MHC molecules. The TCRs 
are highly selective against peptide-HLA complexes presented by cancer cells and affinity 
matured to picomolar affinity. The mode of action of these molecules consists of binding of 
the TCR–domain to cancer cells and redirection of polyclonal T-cells via the anti-CD3 
fragment. Recruited T-cells will then form an immunological synapse and destroy target 
tumour cells. Notably, ImmTACs can redirect T-cells even if these are not specific for the 
target in question. To select tumour-specific targets Immunocore has a large database of 
MS-validated peptide epitopes from normal and cancer cells. As ImmTACs are human-
specific, selectivity and safety screens are done using a fully human in vitro approach using 
cell and tissue models (1). 
In the second part of his talk Dr. Dukes outlined the key data and status of Immunocore’s 
leading clinical molecules. He began with Tebentafusp (IMCgp100), the most advanced drug 
that is currently in pivotal registrational clinical studies for metastatic uveal melanoma. 
Importantly, this molecule has provided clinical proof-of-concept (PoC) for the ImmTAC 
platform with evidence for clinical activity and potential patient benefit in uveal and cutaneous 
melanoma. The activity in ocular melanoma is particularly noteworthy as this hard-to-treat 
cancer type is insensitive to checkpoint inhibitors and has a low mutational burden. Two 
further ImmTAC molecules, directed against tumours positive for NY-ESO-1 (IMCnyeso, 
partnered with GSK) and MAGE-A4 (IMC-C103C, partnered with Genentech) are in Phase I 
clinical development stage. Due to the much broader tumour expression profile of these 
targets Immunocore expects applicability in a wide range of cancers. Dr. Dukes concluded 
that Immunocore has now built a strong emerging pipeline for internal and partnered 




Session 3: Small molecule approaches 
 
Going beyond combinations, bi-specific and bi-functional approaches in IO 
Dr Tilo Senger (Development Program Lead in Oncology/Immuno-oncology) eloquently 
described aspects of Merck KGaA’s research in an excellent talk. He began by presenting 
the options for addressing the challenges that face the immuno-oncology development 
community. Dr Senger then outlined Merck KGaA’s twin paradigm of developing 
bifunctionals/bispecifics with strong rationale of superiority vs. combinations of two 
compounds for the same targets and advancing effective partnerships with 
academia/biotech/pharma to maximise resource and permit the integration of emerging 
technologies. His talk centred on three development programs that featured different aspects 
of these paradigms. 
 Firstly, studies around the investigational tumour-targeting immunocytokine M9241 
(NHS-IL12) (2) were described. This work was conducted in partnership with the National 
Cancer Institute at Bethesda, USA. Preclinical data were presented demonstrating that the 
activity of Avelumab (anti-PD-L1) is increased in combination with NHS-IL12 (3). Treatment 
with NHS-IL12 also led to increased PD-L1 expression in mouse tumours, induction of 
tumour-infiltrating lymphocyte infiltration in EMT6 and MC38 murine models and increased 
proliferation and activation of tumour-associated macrophages, T-cells and NK-cells was 
observed. Indeed, this program has reached an exciting stage; a phase 1b, open-label, 
dose-escalation trial (JAVELIN study design) of NHS-IL12 and Avelumab treatment of 
advanced solid tumours, with sequential assignment of expansion cohorts, is underway and 
primary data are expected in January 2020. 
 
Dr Senger then discussed approaches to targeting Indoleamine 2,3-dioxygenase 1 (IDO1) 
and tryptophan 2,3-dioxygenase 2 (TDO2), key players in establishing immune resistance in 
tumours and catalysing the commitment step of the kynurenine pathway (4). The profile of 
M4112, a dual IDO1/TDO2 inhibitor, was highlighted which offers an opportunity for 
differentiation; IDO1 and TDO2 have distinct natural expression sites and are upregulated on 
different tumour cells. Interesting results from a recent AACR Meeting disclosure (5) on 
clinical responses in a M4112 dose finding trial and unexpected pharmacodynamics effects 
in plasma (limited decrease of kynurenine on day 1 then returning to baseline levels by day 
15) were presented. Further investigation is currently underway. 
 
Dr Senger’s third case study described the discovery of an innovative first-in-class 
bifunctional molecule (Bintrafusp alfa/M7824) in partnership with GSK. It is hoped that this 
TGF-β plus PD-L1 targeting bifunctional fusion protein will overcome poorly addressable 
tumour biology; M7824 exhibits stronger anti-tumour activity to co-administration of TGF-β 
trap and anti-PD-L1 in pre-clinical models (6). He showed promising data that indicated 
durable responses across all PD-L1 expression levels in a phase 1/2 non-small cell lung 
cancer (NSCLC) trial and marked responses in a phase 1 human papillomavirus-associated 
cancer trial. The Merck-GSK Alliance is currently evaluating the potential of M7824 to treat 
difficult-to-treat cancers such as unresectable NSCLC, biliary tract cancer and others, with 
results keenly anticipated. 
 
Small molecule approaches to immune oncology 
To set the scene for his engaging talk, Dr Simon Barry (Senior Principal Scientist and Small 
Molecule Immune-oncology lead at AstraZeneca, Cambridge) stated that the immune-
oncology community is aiming to build on the foundation of PD1/L1 and CTLA4 (7).  Also, 
driving effective anti-tumour T-cell immune responses may be accomplished by targeting 
the tumour microenvironment (to reverse immunosuppression) or tumour cells (to enhance 
immune engagement) or by enhancing immune priming and sustaining T-cell activation.  
 
Dr Barry described the fact that targeting PI3Kα/(using AZD8835) appeared to be superior 
in his team’s hands than targeting PI3K alone (using PI-3065) for driving 
immune-dependent anti-tumour activity in a CT-26 syngeneic model (8). The question of 
whether inhibitors of the PI3K pathway have positive or negative effects on the anti-tumour 
immune response was also addressed with the demonstration that PI3K inhibitors dosed 
intermittently are more active in mouse syngeneic models than when dosed continuously 
(8).  He also emphasised that transient suppression of PI3K- regulatory T cells was 
associated with the anti-tumour response following intermittent dosing but sustained 
elevation of CD8+ Tcells was achieved (8). Moving on to the evaluation of mTORC1/2, 
results were shown that Vistusertib and α-CTLA4 checkpoint blockade promotes immune 
anti-tumour responses in the CT26 model (9). In addition, Vistusertib/α-CTLA4 combination 
promotes a non-exhausted, Th1 effector response plus the activity of checkpoint inhibitors 
α-CTLA4, α-PD1 and α-PDL1 is all enhanced with Vistusertib (mTORC1/2) treatment in 
MC38 tumours (9).  
 
Another interesting feature of this presentation involved the hypothesis of using 
unformulated next generation (Gen 2.5) antisense oligonucleotides (ASOs) to degrade 
mRNA of the transcription factor FOXP3 in order to provide anti-cancer benefit. Dr. Barry 
shared results of a collaboration between AstraZeneca and Ionis demonstrating that mouse 
FOXP3 ASOs promote potent FOXP3 downregulation in primary regulatory T-cells and 
deliver monotherapy efficacy in ID8-VEGF and A20 syngeneic models (dosing 50mg/kg 
BIW from d1 post-implantation). Gratifyingly, the immune changes induced by mouse 
FOXP3 ASOs are localised to the tumour (A20 mouse model), rather than the spleen, and 
FOXP3 ASO/PDx combination augments the depth of anti-tumour response. Modulation of 
STAT3 is known to be a global regulator of the tumour microenvironment (10) and Dr. Barry 
proceeded to show that downregulation of STAT3 by the ASO AZD9150 enhances PD-L1 
inhibitor efficacy in the CT26 model. Collaborative efforts indicate that AZD9150 provides 
early evidence of clinical activity (11) in diffuse large B-cell lymphoma and lung cancer and 
in combination with durvalumab (PD-L1 inhibitor) for the treatment of head and neck 
squamous cell carcinoma. 
 
Specific tumour metabolites are thought to play a pivotal role in regulating T-cell function. 
Adenosine signaling also offers a therapeutic opportunity by tackling the immune 
suppressive tumour microenvironment. Dr. Barry shared data for the A2AR inhibitor 
AZD4635’s (licensed from Heptares) ability to potently reverse adenosine mediated 
suppression of CD8+ T-cell activity and reduce tumour volume in combination with 
anti-PD-L1 monoclonal antibody in MC38 and MCA205 models. Targeting lactate transport 
offers yet another potential therapeutic approach (12).  For example, the MCT4 inhibitor 
AZD0095 exhibits efficacy at 30mg/kg oral dosing BID in a MC38 MCT1 knockout model in 
combination with checkpoint inhibitors using various mass spectrometry techniques 
including MS imaging tumour cell lactate sequestration caused by AZD0095 has been 
analysed and the associated increased infiltration of immune cells to be imaged by mass 
cytometry. 
 
Tumour genetics are likely to be important regulators of the response to immunotherapy. 
Loss of the phosphatase and tensin homolog PTEN promotes resistance to T cell-mediated 
immunotherapy (12). Dr Barry informed the meeting that PTEN-mediated immune 
resistance may be reversed by administration of the PI3Kbeta inhibitor GSK2636771. 
Similarly, in the context of BRCA mutation positive anti-tumour activity of the PARP inhibitor 
Olaparib (AZD2281) is achieved combination with anti-PD-L1 in a BRCA mutant syngeneic 
model. 
 The talk concluded with an impressive overview of the challenges facing the 
immune-oncology field. While there remains a sizeable opportunity around tumour-targeted 
combinations, Dr. Barry pointed out that non-clinical disease models remain suboptimal for 
effective decision-making, signals beyond the backbone therapy are currently limited and 
that increasing response rate in each disease segment is problematic. We are entering an 
exciting season in immune-oncology treatment with features associated with response 
emerging in some settings. 
 
Session 4: Vaccines and gene therapy 
 
Targeted immunotherapy for pre-invasive human papillomavirus disease 
Professor Lucy Dorrell (Head of Translational Medicine - Infectious Diseases at 
Immunocore and Professor of Immunology at the Nuffield Department of Medicine within 
the University of Oxford) gave an insightful presentation into the progress that her team and 
collaborators have made in developing therapeutic vaccines for high risk (oncogenic) 
human papillomaviruses (hrHPV). hrHPV are responsible for a substantial disease burden 
globally, comprising virtually all cervical cancers and a high proportion of anogenital and 
head and neck cancers (14). Importantly, cervical cancer is the second leading cause of 
cancer death in women living in low/middle income countries, where access to cervical 
screening and prophylactic vaccines is limited (15). Globally, it is predicted that 600,000 
women will be diagnosed in 2020, rising to 1.3 million a year in 2069, mainly due to the 
increasing size and average age of the population (15).  
Therapeutic vaccination is a highly attractive, feasible and non-invasive approach to 
eliminating persistent hrHPV infection and cervical intraepithelial neoplasia (CIN) (16).  
Professor Dorrell and her team at Oxford have led the development of a potent 
heterologous viral vector “prime-boost” platform (a replication-defective chimpanzee 
adenovirus, ChAdOx1 (16), and modified vaccinia Ankara, MVA (17) to deliver a unique, 
bioinformatically designed HPV immunogen. '5GHPV3' comprises sequences from the 6 
early proteins that are conserved across 5 high-risk genotypes including HPV16 and 
HPV18. In mouse models, they detected high frequencies of polyfunctional CD8+ and 
CD4+ T cells specific for 5GHPV3 in both the circulation and the cervix following systemic 
administration of viral vectored 5GHPV3 vaccines. HPV-specific T cells persisted for at 
least 6 weeks and were targeted to all early proteins in outbred mice. 
In parallel, Professor Dorrell’s team are also conducting a prospective observational 
longitudinal study to explore the immunological correlates of viral clearance and persistence 
in women with current or prior hrHPV infection. One hundred and forty-five women aged 16-
55 years have been recruited to date, with nearly half completing one year of follow-up to 
date. Up to 20% women had detectable T-cell responses to reference early protein 
sequences from HPV16 and HPV52, the majority of whom also made responses to 
5GHPV3-derived peptides. This data confirmed the relevance of their immunogen 
sequence to natural hrHPV control.  
Professor Dorrell concluded by stating that, based on their encouraging preclinical data, 
GMP manufacture and preclinical toxicology of their vaccines is underway in preparation for 
a proof-of-concept clinical trial in women with low-grade cervical HPV lesions. In addition, 
this vaccine technology has potential application to other populations including HIV+ 




Systemic delivery of localized combination immuno-gene therapy within the tumour 
microenvironment 
Dr David Krige (Director of Translational Medicine, PsiOxus Therapeutics) gave an excellent 
overview of the novel and versatile oncolytic adenoviral vector platform for the selective 
systemic delivery of tumour-specific immuno-gene therapy (T-SIGn) that has been 
established by PsiOxus Therapeutics.  
The platform was developed using a directed evolution process that involved passaging a 
very large randomly created library of chimeric adenoviruses repeatedly on human carcinoma 
cells, selecting for the most potent tumour killing viruses and then back-selecting these for 
lack of activity against normal human cells. The most potent of these were then screened 
against human carcinoma cells in the presence of fresh human blood to ensure stability and 
therefore suitability for intravenous systemic delivery. This resulted in the final selection of a 
viral vector known as Enadenotucirev (EnAd), which forms the basis of the platform (19). 
EnAd consists of an Ad11 capsid, to which there is low pre-existing immunity, a chimeric 
Ad11/Ad3 E2B region and deletions in E3 and E4orf4. In preclinical models, EnAd has 
demonstrated broad spectrum, potent anti-tumour activity and tumour selective replication. 
In cancer patients, EnAd has displayed a predictable and manageable safety profile following 
systemic (IV) dosing (20) as well as virus delivery and selective replication in tumour cell (21).  
The deletions in the genome provide space for the insertion of multiple custom transgenes 
under the control of the virus major late promoter, allowing the EnAd vector to be armed while 
maintaining its tumour selective properties – “T-SIGn” viruses. Given that the encoded 
therapeutics are expressed from the virus major late promoter, products are only made in 
cells supporting virus replication, i.e. tumour cells. T-SIGn genome modification produces no 
changes to the structural properties of the virus particles, and several different therapeutic 
transgene payloads can be encoded within a single virus without impacting virus or payload 
production levels (up to 5, with a cloning capacity of approximately 3kb). This approach has 
several advantages, including: 
 Intravenous systemic delivery of the viral vector but local production of biologics within 
tumour tissues, thereby enhancing local effects in the tumour microenvironment while 
minimizing systemic toxicities 
 The use of novel therapeutic approaches for molecules with poor PK or which are 
poorly tolerated when dosed systemically. 
A pipeline of T-SIGn candidates, differentiated by mechanism and targeted patient 
populations, are in both preclinical and clinical development. Dr Krige gave an overview of 
two such products; NG-641 (expressing fibroblast activating protein (FAP)-targeting 
bispecific T-cell activator (FAP-TAc), CXCL9, CXCL10 and IFNα transgenes), and NG-350A 
(anti-CD40 agonist antibody).  
Extensive preclinical data were presented demonstrating that NG-641 has the desired anti-
tumour properties including the ability to induce rapid activation of T-cells and killing of 
stromal fibroblasts, and to promote the selective T-cell mediated killing of FAP+ fibroblasts 
by infected tumour cells in primary malignant cell cultures leading to decreased TGFβ levels. 
Because in cold tumours the activity of FAP-TAc alone may be limited by insufficient T cells, 
NG-641 includes CXCL9 and -10 to induce the migration of T cells and IFNα to drive innate 
immune cell (e.g. dendritic cell) activation and T-cell priming. A wide-ranging translational 
strategy for clinical trials has been developed which will use multiple different experimental 
methods, designed to investigate virus delivery to, and transgene expression within, tumours 
(proof of mechanism), the immune effects of virus/transgene (proof of principle and 
pharmacodynamic readouts) and potential predictive biomarkers. 
The second T-SIGn candidate presented by Dr. Krige (NG-350A) has already reached the 
clinic and is currently in a multi-centre, open-label, first-in-human Phase I trial 
(NCT03852511). The study was initiated in February 2019 and will examine safety, tolerability 
and preliminary efficacy of NG-350A together with virus kinetics, immunogenicity and other 
pharmacodynamic effects in patients with advanced or metastatic epithelial tumours. The 
Phase IA dose escalation phase will investigate NG-350A given to patients by IV infusion on 
Day 1, 3 and 5. A parallel cohort will be given a single dose of NG-350A by intra-tumoral 
injection on Day 1 to provide an opportunity to perform translational research. Phase IB of 
the study, using the recommended dose from Phase IA, will investigate efficacy in up to three 
separate IV dosed cohorts of patients with epithelial tumour types. 
In summary, PsiOxus have developed a platform that allows selective systemic delivery of 
tumour-specific immuno-gene therapy (T-SIGn) combinations locally within tumour tissues, 
thereby providing a route for “gene therapy” of cancer. They have a pipeline of candidates, 
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